Clinical
ciliary muscle.33 In the current study, latanoprost did not lower
IOP. The drug was discontinued in three glaucomatous eyes,
but continued in conjunction with topical dorzolamide and
prednisolone in one glaucomatous eye (Case 2). The develop-
ment of iris pigmentation in this case suggested an age-related
phenomenon, however, the markedly darker iris in the treated
eye may have been the result of a drug-induced pigmentation,
which has been reported to occur in humans.34
affected eyes maintained vision for 2 to 4 years when appropri-
ately managed. Evidence of poorer vision and “tunnel-like
vision”, as described by owners, only became apparent in some
cats during the last 6 months of the study. Thus, primary glau-
coma in these cats was an insidious, chronic, progressive optic
neuropathy in which visual field damage was delayed. A similar
presentation has been reported for canine primary glaucoma in
the Norwegian Elkhound and Chow Chow breeds, in which
vision is maintained despite elevated IOP, buphthalmos and
obvious extensive optic nerve head degeneration.13
Optic nerve cupping indicates a weakening of the scleral
lamina cribosa, a porous structure through which optic nerve
axons pass at the optic nerve head region. Increased IOP pushes
this area posteriorly, thereby causing mechanical compression of
axons and microcirculatory abnormalities.13,20 The ganglion
cells and inner retinal neurons, especially in the peripheral
retina, are particularly sensitive to elevated IOP and a cascade of
tissue and vascular events leads to their death.13, 20 The under-
lying mechanisms for the retinal and optic disc changes are due
only in part to increased IOP; other factors include the release
of glutamate and other neuroexcitatory chemicals.21 Despite
current research into the role of anti-inflammatory and cryopro-
tective agents in reversing or preventing these mechanisms,
there are currently no controlled clinical studies to support the
use of these agents.21
All cats in this study received topical prednisolone either as
0.5% or 1.0% solution. This drug is frequently used in cases of
secondary glaucoma to reduce intraocular inflammation. In this
study, it was used to reduce the inflammatory changes associ-
ated with glaucoma. It is thought by one author (RS) that a low
grade inflammation is present in all glaucomas. Longterm
control of inflammation may prevent or delay repeat pressure
spikes and help maintain vision, however, the use of longterm
topical steroids has also been associated with elevated IOP in
35
normal cats. The development of cataracts may have also
been caused by the longterm use of topical steroids35 or by the
well-known side effects of diode laser therapy.12
Surgery was frequently required in this study to regain
normotension in eyes in which IOP was greater than 30 mm
Hg. However, comparison of the efficacy in lowering IOP
between the different cyclocryothermy techniques was not
possible in this study. Cyclocryothermy with liquid nitrogen has
been reported to give the best results due to its rapid freeze and
slow thaw of tissues, which is advantageous in cryodestruc-
tion.36 Diode laser surgery in the present study produced fewer
traumatic side effects, although corneal ulceration was a
problem, especially if topical prednisolone was used concur-
rently. Histologic studies have revealed that transscleral diode
laser cyclophotocoagulation in the normal canine eye produces
focal coagulative ciliary body necrosis.37 However, the success of
diode laser surgery depends on the amount of melanin in the
tissue and cats with a lightly pigmented iris may not absorb
sufficient laser energy for adequate cyclodestruction.12
In conclusion, the findings in this study support several
recommendations for the diagnosis and management of feline
primary narrow-angle glaucoma. Firstly, injected episcleral
blood vessels should be recognised as an early marker for glau-
coma, which then can be confirmed with tonometry. Secondly,
medical treatment should be commenced early with topical 2%
dorzolamide at three times daily and if the IOP is not respon-
sive to this drug alone, the addition of cyclodestructive surgery
is required. Finally, good client communication and compliance
with regular monitoring is manditory in the management of
these patients, as this condition is progressive and, while it can
be controlled, it cannot be cured.
Earlier clinical studies of feline glaucoma report a poor
6, 9
response to medical or surgical therapy,
possibly because of
the late presentation of these cases and the use of less efficacious
drugs. A recent clinical study reports greater success in main-
taining vision and controlling IOP with the use of topical
ophthalmic medications such as dorzolamide and latanoprost,
when used alone or with other antiglaucoma medications.4 In
the present study, antiglaucoma drugs were selected for their
efficacy in lowering IOP and for being non-irritant in cats.
Thus topical pilocarpine, an effective drug for lowering IOP in
normotensive cats,22 was not used because it was considered too
irritant. Initially, timolol maleate, a non-selective β-adrenergic
blocker that lowers aqueous humour production,23 was selected.
The use of timolol in lowering IOP in normal cats has been
previously described,24 but did not appear efficacious in our
study. Dorzolamide, a topical carbonic anhydrase inhibitor
which in humans decreases the production of aqueous produc-
tion without systemic side effects,25,26 has also been shown to
lower IOP in normal and glaucomatous dogs when applied
three times daily.27,28 Whereas dorzolamide was used in all
affected cats in this study, it is not possible to comment on the
efficacy of this drug alone, because surgical cyclodestructive
procedures were also required to control IOP. In the present
study, one cat could not tolerate dorzolamide, and, possibly as a
consequence of its withdrawal, IOP in this cat was not well
controlled. Similar side-effects of dorzolamide in cats have been
described elsewhere.4
Acknowledgments
Financial support was provided by the Brisbane Veterinary
Practitioners Group and VPS-IDEXX. We acknowledge the
following veterinarians for the referral of cases: Drs C Caesar, F
Galloway, M Gunew, V Menrath, M Ryan, S Steiner-Bakker
and C Stewart. Special thanks are given to the cats and their
owners who have made this study possible.
Latanoprost, a recently introduced prostaglandin agonist, was
also used topically on four glaucomatous eyes in the present
study. This drug increases the outflow of aqueous fluid through
the uveoscleral pathway, an alternative to the usual drainage site,
in humans,29 monkeys and rabbits.30 Although latanoprost is
widely and successfully used in canine primary glaucoma, its
clinical efficacy in cats is controversial,4,31 especially since only
3% of aqueous drainage in the cat occurs through the
uveoscleral pathway.32 Futhermore, the FP receptor, the site by
which IOP is lowered by latanoprost, is absent in the feline
References
1. Ritch R, Shields MB, Krupin T. Preface. In: Ritch R, Shields MB, Krupin T,
editors. The Glaucomas. 2nd edn. Mosby-Year Book, St. Louis, 1996:xvii-xviii.
2. Glaze MB, Gelatt KN. Feline Ophthalmology. In: Gelatt KN, editor. Veterinary
Ophthalmology. 3rd edn. Lippincott, Williams and Wilkins, Baltimore 1999:997-
1052.
Aust Vet J Vol 80, No 11, November 2002
679